Gilead Sciences to acquire British biotech company MiroBio for $405m

pallavi123- August 6, 2022 0

Gilead Sciences has agreed to acquire MiroBio, a clinical-stage British biotech company, in an all-cash deal worth around $405 million in a move to gain ... Read More

India grants emergency approval to Covishield and Covaxin vaccines for Covid-19

pharmanewsdaily- January 3, 2021 0

In a significant development in the battle against Covid-19, the Drugs Controller General of India (DCGI) has granted emergency approval for two vaccines—Covishield, developed by ... Read More

India’s DCGI grants emergency approval to Covishield and Covaxin vaccines

pharmanewsdaily- January 3, 2021 0

In a major step forward in India’s fight against the Covid-19 pandemic, the Drugs Controller General of India (DCGI) has granted emergency use approval to ... Read More

Oxford develops rapid diagnostic test to detect Covid-19 within 5mins

pharmanewsdaily- October 16, 2020 0

Oxford University claimed that scientists from its Physics department have developed an extremely rapid diagnostic test for Covid-19. The rapid diagnostic test can detect and ... Read More

COV001 clinical trial results : Oxford vaccine ChAdOx1 nCoV-19 triggers strong immune response

pharmanewsdaily- July 20, 2020 0

COV001 clinical trial results : AstraZeneca and Oxford University said that interim results from the phase 1/2 COV001 clinical trial showed the ChAdOx1 nCoV-19 vaccine ... Read More

ChAdOx1 nCoV-19 vaccine : Russia’s R-Pharm signs deal with AstraZeneca

pharmanewsdaily- July 17, 2020 0

Russian pharma company R-Pharm has reportedly signed an agreement with AstraZeneca for manufacturing the ChAdOx1 nCoV-19 vaccine being developed by the latter in collaboration with ... Read More

Oxford University ChAdOx1 nCoV-19 vaccine trial begins in humans

pharmanewsdaily- April 25, 2020 0

Researchers at the University of Oxford in the UK have commenced the ChAdOx1 nCoV-19 vaccine trial in healthy human volunteers to test the vaccine candidate's ... Read More

Evox Therapeutics secures £35.5m in Series B to advance exosome therapeutics

pharmanewsdaily- September 4, 2018 0

Evox Therapeutics, an innovative biotechnology company spun out from Oxford University, has successfully raised £35.5 million in a Series B financing round. The round was ... Read More